Home › Ulcerative Colitis › Minnesota › Rochester
Ulcerative Colitis clinical trials in Rochester, MN
5 studies for Ulcerative Colitis are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
RecruitingPhase 2
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RecruitingPhase 2
- Site 028, Rochester
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
Recruiting
- Mayo Clinic, Rochester
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RecruitingPhase 2/3
- Mayo Clinic in Rochester, Minnesota, Rochester
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RecruitingPhase 1
- Mayo Clinic, Rochester
About Ulcerative Colitis
Ulcerative Colitis (UC) can cause long-lasting swelling and ulcers in the large intestine. It is a type of inflammatory bowel disease. Find out more.
More about Ulcerative Colitis on MedlinePlus
Ulcerative Colitis trials in other cities
- Orlando, FL21 studies
- New York City, NY21 studies
- Miami, FL20 studies
- Houston, TX14 studies
- San Diego, CA13 studies
- Chicago, IL13 studies
- Tacoma, WA13 studies
- St. Louis, MO13 studies
- Tyler, TX13 studies
- San Antonio, TX13 studies
- Colorado Springs, CO12 studies
- Boston, MA12 studies
Other studies in Rochester
- Breast Cancer39 studies
- Non-Small Cell Lung Cancer38 studies
- Cancer (all types)31 studies
- Metastatic Cancer28 studies
- Ovarian Cancer27 studies
- Colorectal Cancer27 studies
- Multiple Myeloma25 studies
- Heart Failure21 studies
- Lung Cancer21 studies
- Prostate Cancer20 studies
- Pancreatic Cancer20 studies
- Chronic Lymphocytic Leukemia20 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.